Lab Incube, specializing in the development of MOF (Metal-Organic Framework)-based porous materials, has secured a significant Series B investment of 14.7 billion won. This funding round saw the participation of new strategic investor MetaBiomed, a global biodegradable medical material company, in addition to follow-on investments from existing investors such as BNHI Investment, Union Investment Partners, and JK Partners. With this investment, Lab Incube plans to advance its MOF material-based platform and focus on expanding its business significantly.

In conjunction with the investment, Lab Incube and MetaBiomed have established a strategic partnership through joint research and development, as well as co-commercialization agreements. The collaboration aims to combine Lab Incube's unique technology with MetaBiomed's manufacturing infrastructure to work together in the global medical device market, targeting innovations like next-generation polymer fillers. CEO Choi Kyung-min expressed confidence in the reinforced business capabilities brought about by the backing of a solid strategic partner and insisted that this investment would serve as a springboard for developing their MOF material platform, ultimately yielding significant competitive advantages in the fields of chemistry and biosciences.

Lab Incube, which emerged from professor Choi's entrepreneurial efforts, has previously achieved notable distinctions, including being recognized as an 'infant unicorn' by the Ministry of SMEs and Startups. The company reportedly made groundbreaking progress by successfully commercializing an MOF material that led to its recognition for the 2025 Nobel Prize in Chemistry. Their proprietary material platform, CUBRIX™, offers precision control over molecular spacing and designs spaces of desired sizes, laying the groundwork for innovative applications, including advanced filters for air and water treatment, as seen in LG Electronics' products.